Cytel
applies AI to HEOR through case studies navigating regulatory and HTA guidance, alongside its established biostatistics practice, and analyzes potential impacts of US drug-pricing reform on pharma HEOR evidence generation.
- Country
- United States
US
Coverage
| EU | US | |
|---|---|---|
| regulatory-legal | ✓ | ✓ |
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Health economics and outcomes research (HEOR) services | regulatory-legal | Low | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.